Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Miyawaki E, Kenmotsu H, Mori K, Harada H, Mitsuya K, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Endo M, Nakasu Y, Gon Y, Takahashi T. Miyawaki E, et al. Among authors: kobayashi h. Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):604-613. doi: 10.1016/j.ijrobp.2019.02.051. Epub 2019 Mar 6. Int J Radiat Oncol Biol Phys. 2019. PMID: 30851347
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
Miyawaki T, Kenmotsu H, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Deguchi S, Mitsuya K, Naito T, Murakami H, Mori K, Harada H, Hayashi N, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: kobayashi h. Invest New Drugs. 2021 Dec;39(6):1732-1741. doi: 10.1007/s10637-021-01140-3. Epub 2021 Jul 14. Invest New Drugs. 2021. PMID: 34259953
Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer.
Miyawaki T, Naito T, Doshita K, Kodama H, Mori M, Nishioka N, Iida Y, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Mori K, Harada H, Endo M, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: kobayashi h. Thorac Cancer. 2022 Jul;13(14):2064-2074. doi: 10.1111/1759-7714.14529. Epub 2022 Jun 13. Thorac Cancer. 2022. PMID: 35698259 Free PMC article. Review.
Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Omori S, Kenmotsu H, Abe M, Watanabe R, Sugino T, Kobayashi H, Nakashima K, Wakuda K, Ono A, Taira T, Naito T, Murakami H, Ohde Y, Endo M, Akiyama Y, Nakajima T, Takahashi T. Omori S, et al. Among authors: kobayashi h. Int J Clin Oncol. 2018 Dec;23(6):1052-1059. doi: 10.1007/s10147-018-1305-4. Epub 2018 Jun 15. Int J Clin Oncol. 2018. PMID: 29948239
Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
Miyawaki T, Kenmotsu H, Mori K, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Harada H, Endo M, Ohde Y, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: kobayashi h. Clin Lung Cancer. 2020 Sep;21(5):e405-e414. doi: 10.1016/j.cllc.2020.02.012. Epub 2020 Feb 26. Clin Lung Cancer. 2020. PMID: 32205040 Clinical Trial.
Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.
Omori S, Muramatsu K, Kawata T, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Sugino T, Takahashi T. Omori S, et al. Among authors: kobayashi h. J Cancer Res Clin Oncol. 2022 Sep;148(9):2455-2463. doi: 10.1007/s00432-021-03784-3. Epub 2021 Sep 17. J Cancer Res Clin Oncol. 2022. PMID: 34533624
9,318 results